SCHEMBL2860565

SCHEMBL2860565

O=C(O)c1n[nH]c2c1CCCCC2Cc1cccc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.70
HCAR2 Q8TDS4 7/20 0.45
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX2 P34913 1/20 0.40
CDKN1A P38936 1/20 0.39
KMT2A Q03164 2/20 0.39
PARP1 P09874 1/20 0.38
GLA P06280 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
TSHR P16473 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3466331 1.00 CNR2 (0.70) CNR2HCAR2LMNANPC1ALDH1A1
SCHEMBL3469536 1.00 CNR2 (0.70) CNR2HCAR2LMNANPC1ALDH1A1
SCHEMBL8282615 0.84 HCAR2 (0.55) CNR2HCAR2CDKN1AKMT2ATSHR
SCHEMBL176480 0.84 CNR2 (0.80) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL14259000 0.84 CNR2 (0.80) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL176535 0.84 CNR2 (0.80) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL14089789 0.84 CNR2 (0.80) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL176651 0.83 CNR2 (1.00) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL13746011 0.83 CNR2 (1.00) CNR2LMNANPC1ALDH1A1RAB9A
SCHEMBL13745625 0.83 CNR2 (1.00) CNR2LMNANPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378117-B2 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US claimed
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US claimed
EP-2139328-A2 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-01-06 EP claimed
EP-2139326-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN Janssen Pharmaceutica, N.V. (BE) 2010-01-06 EP claimed
US-20090197886-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-08-06 US claimed
JP-2009508953-A 2009-03-05 JP claimed
WO-2008115705-A2 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-25 WO claimed
WO-2008115671-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-25 WO claimed
US-20080234347-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-25 US claimed
EP-1937259-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP claimed
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-20 US claimed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US claimed
WO-2007038036-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-05 WO claimed
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US disclosed
US-8378117-B2 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US disclosed
EP-2139326-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN Janssen Pharmaceutica, N.V. (BE) 2010-01-06 EP disclosed
EP-1937259-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-20 US disclosed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US disclosed
WO-2007038036-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197886-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS CNR2, CNR1, FAAH CNR2 1/4885HCAR2 11/4885LMNA 4644/4885
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators CNR2, CNR1, FAAH CNR2 1/4885HCAR2 11/4885LMNA 4644/4885
US-20080234347-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN CNR2, CNR1, NPY4R CNR2 1/4885HCAR2 66/4885LMNA 3769/4885
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators CNR2, CNR1, FAAH CNR2 1/4885HCAR2 11/4885LMNA 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.